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In a recent multicenter population pharmacokinetic study of ciprofloxacin administered to 
children suffering from complicated urinary tract infection (cUTI), the apparent volume of 
distribution (Vd) and total plasma clearance (CL) were decreased by 83.6% and 41.5% 
respectively, compared to healthy children. To understand these differences, a physiologically-
based pharmacokinetic model (PBPK) for ciprofloxacin was developed for cUTI children. First, a 
PBPK model in adults was developed, modified incorporating age-dependent functions and 
evaluated with paediatric data generated from a published model in healthy children. Then, 
the model was then adapted to a cUTI paediatric population according to the degree of renal 
impairment (KF) affecting renal clearance (CLRenal,) and CYP1A2 clearance (CLCYP1A2). Serum and 
urine samples obtained from 22 cUTI children were used for model evaluation. Lastly, a 
parameter sensitivity analysis identified the most influential parameters on V and CL. The PBPK 
model predicted the ciprofloxacin exposure in adults and children, capturing age-related 
pharmacokinetic changes. Plasma concentrations and fraction excreted unchanged in urine (fe) 
predictions improved in paediatric cUTI patients once CLrenal and CLCYP1A2 were corrected by KF. 
The presented PBPK model for ciprofloxacin demonstrates its adequacy to simulate different 
dosing scenarios to obtain PK predictions in a healthy population from 3 months old onwards. 
Model adaptation of CLRenal and CLCYP1A2 according to KF explained partially the differences seen 
in the plasma drug concentrations and fe vs time profiles between healthy and cUTI children. 
Nevertheless, it is necessary to further investigate the disease-related changes in cUTI to 
improve model predictions. 
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List of abbreviations 
ADME: Absorption, Distribution, Metabolism and Excretion 
BBD: bladder bowel dysfunction 
BSA: body surface area  
CAKUT: congenital anomalies of the kidneys and urinary tract  
CF: Cystic Fibrosis 
CLBil: biliary clearance 
CLCYP1A2: CYP1A2 mediated clearance  
CLRenal: renal clearance 
cUTI: complicated urinary tract infection  
CYP1A2: cytochrome P450 1A2 
FDA: Food and Drug Administration  
fe: fraction excreted unchanged in the urine 
fu: fraction unbound in plasma in humans 
GFR: glomerular filtration rate  
IV: intravenous 
KF: kidney function 
Kp: tissue-to-plasma partition coefficient 
logP: logarithm of the octanol-water partition coefficient of the neutral form (lipophilicity)  
MW: Molecular Weight  
PBPK: Physiologically-Based Pharmacokinetics 
PK: pharmacokinetics 
pKa acid: negative logarithm of the acid dissociation constant 
pKb basic: negative logarithm of the basic dissociation constant 
PO: oral administration 
TS_CLint: tubular secretion clearance  

















Complicated urinary tract infection (cUTI) is a disease occurring in a patient with a 
structural or functional abnormality of the genitourinary tract[1], and remains one of the most 
common causes of febrile illness in the paediatric population. At ages up to 8 years old, 2% of 
males and 8% of females suffer from at least one episode of UTI[2]. Children with congenital 
anomalies of the kidneys and urinary tract (CAKUT) are at major risk for complications of UTI 
such as sepsis, pseudohypoaldosteronism, renal scarring or reflux nephropathy, which could 
result in chronic kidney disease[3,4]. 
Ciprofloxacin is a second generation fluoroquinolone with a broad antibacterial spectrum, 
approved for treatment of cUTI in children[5]. Development of resistance of different 
uropathogens to fluoroquinolones, mainly due to their inappropriate use, represents a current 
and alarming unmet clinical need[6]. Given that ciprofloxacin’s antibacterial effects are 
determined by the AUC over the MIC[7], it is fundamental to characterize its pharmacokinetics 
(PK) in the target populations to optimize drug exposure avoiding toxicity and minimizing 
resistance. Such characterization is not trivial to achieve in the case of paediatric patients 
suffering from certain diseases like cUTI, as shown below. 
Ciprofloxacin undergoes glomerular filtration and tubular secretion (TS_CLint), which 
together, account for about 60% of the total clearance (CL) in adults. Non-renal CL involves 
CYP1A2 mediated metabolism (CLCYP1A2) and biliary excretion (CLBil). Ciprofloxacin´s oral 
bioavailability is approximately 70% and its binding to albumin ranges between 20% to 40%[5]. 
Ciprofloxacin´s PK have been characterized for a cystic fibrosis (CF) adult population using a 
two compartment model with a total apparent volume of distribution (Vd) of 1.1 L/kg and a 
total clearance (CL) of 0.34 L/h/kg[8]. Age, body weight, serum creatinine concentration and CF 
status have been identified as covariates in different previous population analyses in the 
paediatric population[9,10]. 
Recently, Meesters et al.[11] have developed a population pharmacokinetic model of 
ciprofloxacin in children with cUTI finding that Vd and total plasma CL were 83.6% and 41.5% 
reduced, respectively, with respect to healthy children and paediatric patients with CF[9,10]. 
These findings are in accordance with previous observations, indicating that renal impairment 
affects drug disposition beyond the impact on renal clearance[12]. 
Moreover, those results highlight the difficulty to establish an optimal dose and predict 
individual patients’ dosing as the label specifies that paediatric patients with moderate to 
severe renal insufficiency were excluded from the clinical trial of cUTI and pyelonephritis[5]. In 
this context, physiologically-based pharmacokinetic (PBPK) modelling appears best suited to 
identify and potentially predict the impact of physiopathological alterations occurring in cUTI 
on the PK of ciprofloxacin in children, particularly in young infants, as PBPK models incorporate 
growth changes and maturation in processes that are known to alter drug disposition[13], 
together with disease related factors. The current evaluation appears timely as the interest in 
PBPK modelling is increasing in general, and also in the particular case of ciprofloxacin, where a 

















PBPK models are regularly being applied to describe a compound’s behaviour in otherwise 
healthy children, but their use in paediatric disease states affecting one or more of the 
eliminating organs is less well documented. Based on the above considerations, the goal of the 
present study was to develop a PBPK model in the paediatric population with cUTI, and 
identify physiological aspects that may be responsible for altered PK in children with cUTI as 
compared to a healthy population.  
2. METHODS 
2.1. Description of the PBPK model development workflow, clinical data and 
software used   
In this work, an FDA guidance-based workflow for PBPK model development in children 
was used[15]. In a first step, a PBPK model for ciprofloxacin in the adult population was 
developed and challenged to predict systemic concentrations after intravenous (IV) and oral 
(PO) administration. Then, the established PBPK model in adults was extrapolated, 
incorporating age-dependent physiological and anatomical changes to generate plasma 
ciprofloxacin concentrations for IV and PO administration in children. Finally, the PBPK model 
developed in healthy children was adapted to the paediatric population suffering from cUTI 
according to the patient´s individually determined kidney function (KF). Lastly, a parameter 
sensitivity analysis was performed to identify the most influential parameters on V and CL. 
Fig. 1 shows the workflow used in this work specifying each step of the model 
development, the type of data and the corresponding source used for model building. Briefly, 
mean ciprofloxacin plasma concentration versus time profiles in adults after IV or PO 
administration were obtained from literature[16–21]. The population PK model developed by 
Rajagopalan and Gastonguay[9] for ciprofloxacin in children with normal kidney function or 
mild renal impairment, was used to simulate typical ciprofloxacin PK profiles in plasma of 
healthy children. Raw data obtained from a clinical study performed in paediatric patients with 
cUTI were used to adapt the PBPK model established for that particular paediatric population. 
Supplementary Table S1 and Table 1 summarize the design characteristics of those studies 
performed in adults and children. 
Fig1. Model building steps, type of data and the corresponding source. IV intravenous, PO oral. 
The software WebPlotDigitizer® v.3.8 was used to extract the concentration versus time 
data from the adult literature studies. The software used for the PBPK model building was PK-
Sim® v.7.2.1 (http://open-systems-pharmacology.org). NONMEM® v.7.4 (Icon Development 
Solutions, Ellicott City, MD, USA) was used to perform the simulations of the PK profiles in 
plasma using the model and parameters publicly available[9]. R® v.3.3.2 and RStudio® 
v.1.0.136 were used for the graphical representation and preparation of the data sets. 
2.2. Adult PBPK model development and evaluation 
The standard whole human body for PBPK modelling in PK-Sim® consists of 18 
compartments, representing relevant organs and tissues of the body connected with arterial 
and venous blood flows to allow inter-compartmental mass transport. Each compartment is 
















interstitial space and intracellular space). Supplementary Fig. S1 shows a schematic 
representation of the default PBPK model implemented in PK-Sim®[22]. Drug-related 
information must be provided to characterize the absorption, distribution and elimination 
processes. Physicochemical properties were gathered from the literature (Table 2), and 
clearance inputs were estimated as described below. Tissue-to-plasma partition coefficients 
(Kp) were predicted using the equations proposed by Rodgers et al. [23]. The physiological 
model parameters implemented in PK-Sim® v.7.2.1 are described in the software manual and 
they can be found by exporting a simulation from PK-Sim® to MOBI® and afterwards, exporting 
to MATLAB®[22]. 
Ciprofloxacin undergoes both renal and non-renal elimination. Renal clearance (CLRenal) 
exceeds the value of the product between fu and the glomerular filtration rate (GFR; 125 
mL/min/1.73 m2) indicating a contribution of active tubular secretion[5]. Because the specific 
transporter(s) involved in the tubular secretion of ciprofloxacin are not well defined[27,28], 
and to ensure full characterization of the renal elimination, an efflux transporter was 
considered at the apical side of the kidney with a contribution to CLRenal, in addition to 
glomerular filtration, represented by TS_CLint with a value that was estimated as explained 
below. CYP1A2 mediated metabolism[5] and biliary excretion were represented by CLCYP1A2 and 
CLBil, respectively. Taking into account that (i) approximately 15% of an IV dose is recovered 
unchanged in faeces within 5 days after dosing[5], (ii) biliary secretion is not age dependent in 
the range from 3 months to 18 years[28] and (iii) ciprofloxacin possesses a total plasma CL of 
8.34 mL/min/kg for a healthy 70 kg adult[16,17,21], the value of CLBil used in our analysis was 
assumed to be 1.25 ml/min/kg. 
Mean plasma concentration and fraction of the administered dose excreted unchanged in 
urine (fe) profiles were used as raw data following IV administration[16,17,21] to estimate the 
parameters TS_CLint, and CLCYP1A2 assuming linear PK[5] and average demographic 
characteristics (supplementary material Table S1) using a Monte Carlo estimation method. 
Once disposition was characterised, mean data obtained after PO administration[16–20] 
were described, using information regarding the type of pharmaceutical formulation, and 
assuming that the full dose administered is released from the formulation. The tablet particle 
dissolution was quantified by a Weibull function with no lag time, a shape factor of 0.80 and 4 
hours for the 50 % dissolution time[25]. Subsequently, transcellular specific intestinal 
permeability was optimized. 
2.3. Paediatric PBPK model development in healthy children 
Ciprofloxacin physicochemical properties, absorption, distribution, metabolism and 
excretion (ADME) parameters were retained in the paediatric model as determined in the 
adult model. Age-dependent algorithms implemented in PK-Sim® were used to generate 
anatomical and physiological parameters, along with height, body water, body weight, organ 
weights, blood flows, cardiac output and lipid and protein concentrations. Children´s 
ciprofloxacin fu was estimated using the value of fu in adults, and the default albumin ontogeny 
















With respect to elimination, GFR and CLBil were adjusted using age-dependent functions 
proposed by Rhodin et al. [31] and Johnson et al. [29] respectively, as implemented in PK-
Sim®. The ontogeny model published by Hayton[31] developed to describe the excretion of p-
aminohippuric acid was applied for TS_CLint in the current exercise, whereas for the age-
dependent CYP1A2 activity function, the one proposed by Edginton et al. [33] was considered. 
Typical pharmacokinetic profiles for 3, 6, and 18 months, 4, 8, and 12 years old male 
children were then generated assuming a single administration of 9 mg/kg as a 60 min IV 
infusion, or a 15 mg/kg tablet[9], and challenged against the typical predictions obtained from 
the population PK model reported by Rajagopalan and Gastonguay[9] for subjects without 
cystic fibrosis. Typical pharmacokinetic profiles were obtained selecting the individual´s weight 
according to the corresponding age value obtained from the ICRP European population[34].  
2.4. PBPK model for children with cUTI 
The clinical characteristics of the cUTI clinical trial population [11] are summarized in 
Table 1. 
Renal impairment is a potential major consequence of cUTI[4]. The ontogeny model 
implemented in PK-Sim® uses the following physiological variables to predict GFR as suggested 
by Rhodin et al[31]: postmenstrual age, body weight, height, adult GFR and gender. However, 
the model does not incorporate a component accounting for renal insufficiency. 
In order to overcome that limitation, we first calculated individual patient GFR using the 
approach suggested by Chehade[35] and represented in the following expression, since serum 
creatinine (mg/dL), and cystatin C (mg/L) values were available from the patient population, as 
well as gender, height (cm) and post menstrual age (years): 
𝐺𝐹𝑅 = 0.42 ×
𝐻𝑒𝑖𝑔ℎ𝑡
𝑆𝑒𝑟𝑢𝑚 𝐶𝑟𝑒𝑎𝑡𝑖𝑛𝑖𝑛𝑒










Subsequently, the degree of renal impairment (KF) was calculated for each patient as the 
ratio of the above calculation and the ontogeny GFR value (after normalizing it by BSA) using 
the Rhodin et al.[31] approach, and lastly, renal clearance (including filtration and tubular 
secretion) was normalized by KF. 
It has been widely demonstrated that not only renal elimination is altered in patients with 
impaired KF, also hepatic drug metabolism can be affected, either by inducing or suppressing 
expression of hepatic enzymes[12]. Rowland et al. reported a CYP1A2 activity of 63 and 46% 
compared to healthy in the case of chronic kidney disease of stage 3 or 4-5, respectively[12]. 
Accordingly, CLCYP1A2 was reduced by those fractions in patients with KF values between 0.33-
0.65 or lower than 0.33 of the normal (KF= 1), respectively. 
With respect to the change in plasma protein concentrations occurring as a consequence 
of chronic kidney disease, given the low degree of binding of ciprofloxacin (fu ranges between 
20 and 40%), its impact on plasma protein binding was considered to be negligible (as shown in 
















2.5. Model evaluation 
For all models developed and described in sections 2.2-2.4, the PBPK based generated 
profiles either in plasma or in urine were displayed together with either mean published 
profiles, typical population PK model simulations, or individual observed profiles. In addition, 
PBPK based simulated data were plotted against challenged data for predictive performance 
analysis, considering them acceptable when they were within a two-fold prediction error. The 










Where n is the number of points while Pred and Obs refer to the model predicted and 
observed ciprofloxacin plasma concentration or fe. As can be seen, observations are very well 
captured by the model for most of the best and the good fitted individuals. 
2.6. Parameter sensitivity analysis 
To identify physiological aspects that may be responsible for altered PK in children with 
cUTI as compared to a healthy population, a local sensitivity analysis was performed to assess 
the influence of every model parameter on the CL and V, except for the parameters related to 
the drug properties. For this analysis in PK-Sim®, every input parameter (Pi) was varied around 
the value in the simulation by 10% and a new simulation was performed keeping all other 
input values constant. The change in the PK parameter estimate (∆PKj) was calculated as the 
difference between the values in the new simulation versus the original simulation. The 
sensitivity of the PK parameter to the input parameter was calculated as the ratio of the 
relative change of that PK parameter (∆PKj/PKj) and the relative variation of the input 
parameter (∆Pi/Pi) with the equation: (∆PKj/∆Pi)*(Pi/PKj)[22].  
3. Results 
 
3.1. Adult PBPK Model 
Data from several studies following IV or PO administration, conferring a total of 11 
administration protocols, were extracted from the literature [16–21] (supplementary material 
Table S1). The final parameter estimates using the aforementioned data and the drug 
properties from Table 2, are listed in Table 3. As shown in Fig. 2, simulations according to the 
PBPK model well represented the typical observed profiles reported in the studies for different 
types of drug exposure (total plasma concentration, fraction excreted unchanged in the urine, 
and saliva concentration) and for a variety of scenarios including (i) intravenous and oral 
administration, (ii) single and multiple dosing, (iii) different dosage regimens, and (iv) dose 
levels ranging from 200 mg to 750 mg. A slight over- or underprediction at lower 
concentrations can be observed, which may be due to the between-study variability. 
Supplementary Fig. S2A shows that for all scenarios, the observed vs. model simulated 
concentration pairs fall within the two-fold limits of acceptance, in 100% of the cases for IV 
and 93.1% for PO.  
















different administration protocols from the literature[16–21]. Supplementary Table S1 summarizes the 
design characteristics of those studies. Blue, orange and yellow represent ciprofloxacin plasma 
concentration, saliva concentration and fe, respectively. IV intravenous, PO oral, fe fraction excreted 
unchanged in the urine. 
3.2. Paediatric PBPK Model 
Generally, the scaling approach gave adequate results. The profiles represented in Fig. 3 
indicate that the total plasma ciprofloxacin concentrations predicted by the PBPK model are in 
close agreement with the simulations obtained from the published population PK model[9] for 
each of the five age groups explored. A moderate underprediction of IV simulations and a 
modest overprediction of PO can be seen for younger children at lower concentrations. In 
supplementary Fig. S2B it can be seen that 96.9% of the population PK simulated data vs. PK-
Sim® simulated concentrations fall within the two-fold limits of acceptance for the IV 
administration and 95.1% for PO. 
Fig3: Results of the comparison of PK-SIM® predicted (lines) vs. individual NONMEM simulated profiles in 
children (symbols) after IV and PO ciprofloxacin administration for the six representative paediatric ages. 
Simulations represent a single administration of 9 mg/kg as a 60 min IV infusion or 15 mg/kg tablet PO.  
The implemented ontogeny functions developed in healthy children for GFR[31] and 
CLBil[29], and the functions incorporated for active secretion[32] and CYP1A2 activity[33] 
shown in Fig. 4 are appropriate to predict the observations for term children from 3 months to 
18 years old (postnatal age). 
Fig4. Ontogeny functions implemented in the PK-Sim® software (Rhodin et al.[31] for GFR and 
McNamara and Alcorn algorithm[30] for albumin) or incorporated based on the current analysis 
(Hayton[32] for active renal tubular secretion and Edginton et al.[33] for CYP1A2 activity). Light blue 
shadow covers the post menstrual age from the cUTI trial children.   
3.3.   PBPK Model in children with complicated UTI 
In Fig. 5, the PBPK predicted concentration-time profiles are shown for six patients 
receiving ciprofloxacin either IV or PO corresponding to the best, good and worst predictions, 
based on the mean absolute performance error. Only data related to the dosing interval when 
sampling took place are represented. The full profile can be seen in Fig. S4 of the 
supplementary material.  
Fig5. Individual model based simulated (lines) and observed plasma concentrations or fe (solid circles) vs 
time profiles for the best, good, and worse predicted patients. Blue coloured data points and lines 
represent plasma concentrations while the yellow colour represents urine data. The mean absolute 
performance error obtained for each selected patient for plasma concentration and fe, respectively, 
was: ID17: 65%,19%; ID14: 76%,8%; ID19: 146%, 9%; ID4: 21%,12%; ID11: 16%, 46%; ID3: 214.6%, 3%. fe 
fraction excreted unchanged in the urine, KF kidney function.  
Supplementary Fig. S2C shows the PBPK model based predicted vs observed ciprofloxacin 
plasma concentration and fe after IV or PO administration in cUTI paediatric individuals. In the 
case of PO administration, the percentage of predictions located within the two-fold limits of 
















changes in kidney function were considered. On the contrary, differences in those percentages 
were found to be negligible after IV administration. Remarkably, in the current studied 
population, the renal function showed a mean reduction of 16 % with respect to normal, 
ranging from 0.07 to 1. For IV administration, only 30% of subjects presented model predicted 
reduction in KF, whereas in the case of patients receiving ciprofloxacin orally, that percentage 
was increased up to 92%.   
3.4. Sensitivity analysis 
The results from the sensitivity analysis (Supplementary Table S2) revealed that Vd, for 
both healthy (KF=1) and renal impaired (KF=0.5), was greatly affected by the intracellular and 
blood cells pH. Additionally, fu as well as plasma and interstitial pH, together with kidney and 
muscle volume showed a ≥ 2.5% increase or decrease in Vd when the parameters were 
increased by 10%. For CL, the contribution of the fu, kidney and liver volume, tubular and 
biliary secretion were the most influential parameters both healthy (KF=1) and really impaired 
(KF=0.5). All other tested parameters did not result in a ≥ 2.5% increase or decrease in Vd or CL 
when the parameter was increased 10% from the corresponding default value. 
Renal function related patterns were observed for the impact of pH (intracellular and 
blood) and kidney volume in Vd, and for liver and kidney volumes impact in CL.  
4. Discussion 
Dose selection and optimization represents a challenge, especially in the paediatric 
population and even more so in diseased children. Under the premise that drug exposure is 
one of the main factors responsible for treatment success, understanding drug disposition is 
mandatory. Whereas top-down approaches (i.e., compartment-based models) have been 
shown useful where minor extrapolation is required, mechanistic, bottom-up or middle-out 
approaches are warranted to predict drug levels in the context of major changes in body 
physiology, with paediatric PBPK being the recommended paradigm. 
In the current analysis, the PBPK approach has been used to mechanistically describe the 
systemic and urinary ciprofloxacin exposure in children suffering from cUTI, a disease causing 
serious alterations in processes involved in its PK. In fact, a recent pharmacokinetic study of 
ciprofloxacin administered to cUTI children showed that the apparent Vd and the total plasma 
CL were decreased compared to healthy children (up to a 83.6% and 41.5%, respectively), 
presenting a degree of inter-individual variability not explained by any of the patient’s factors 
ranging from 60 to 160% [11]. The lack of literature examples extrapolating from healthy 
subjects to the patient population, thus beyond ontogeny, and towards the population of 
interest, exemplify the novel contribution of the current work within the extensive literature 
on both PBPK and ciprofloxacin[9,14,16–21,36]. 
Data availability in the current project was limited to serum ciprofloxacin concentrations 
and amounts excreted in urine, as well as the patient characteristics and drug properties listed 
in Tables 1 and 2, respectively, i.e. not enough to develop a stand-alone model and promoting 
the use of validated PBPK platforms such as PK-Sim®. The model building approach focused 
















contributions of different elimination pathways. The agreement between simulated profiles 
and published data in healthy adults indicate model robustness, given the different dosing 
scenarios considered. Second, ontogenic relationships corresponding to renal filtration and 
active secretion, as well as CYP1A2 activity[31–33] were used to generate profiles in children, 
which were compared with those obtained based on a previously published population 
pharmacokinetic model[9], showing good agreement. Remarkably, the ontogeny function 
developed for CLCYP1A2, based on probe substrates methoxyresorufin, caffeine and 
ropivacaine[33], performed better than the standard ontogeny model[22]. With respect to 
renal clearance mediated by secretion, its degree of maturation was adopted from the model 
developed for aminohippuric acid[32], which was shown to be appropriate for ciprofloxacin. 
Our model is simpler in its structure, especially regarding the absorption process, than the 
recent model covering the full life span[14], with adequate model performance as can be seen 
in Figs. 2 and 3. Indeed, more than 95% of the observed vs. simulated concentration pairs fall 
within the two-fold limits of acceptance for both healthy adults and children. Therefore, the 
model can be considered appropriate to be used in such population. 
The third step was to adapt the PBPK model developed to the physio-pathological 
condition represented by cUTI. Markers of renal function available for each child comprised 
serum creatinine and cystatin C levels. Renal insufficiency in children was assumed to be 
reflected by the fractional change in the glomerular filtration rate between patients and 
healthy subjects combining the two markers and demographics as suggested by Chehade et 
al.[35]. It is known that chronic renal disease can alter drug disposition beyond renal excretion, 
for example decreasing enzyme expression/activity as it has been reported in the past[37]. In 
the current model, metabolic clearance in children with cUTI was reduced accordingly. Impact 
of chronic renal disease on plasma protein levels has also been reported[38]. Given the low 
degree of binding for the case of ciprofloxacin (between 20-40%), it is however unlikely to 
have a relevant effect on its unbound fraction in plasma. The aforementioned approach agrees 
with previous PBPK works describing PK profiles in patients with altered renal function in 
which scaling factors for different parameters and conditions allowed an accurate PK 
description of different compounds in a renally impaired population[39]. 
 The physiologically-based model described the time-profiles of both plasma and urine 
after IV and PO administration reasonably well, even though a slight model misspecification, 
especially after IV administration, can be observed. It should be taken into account that the 
only adjustment performed was based on creatinine or cystatin C. In fact, this approach 
allowed a better prediction, yet there are a number of drawbacks. For example, the KF 
estimation method is generally associated with GFR assuming that tubular secretion is 
proportionally related to GFR, which might not represent the real scenario. This approach does 
not take other alterations in kidney physiology into account, i.e. 52% of the children from the 
cUTI trial had an estimated KF higher than 90% of the healthy function, suggesting other non-
GFR-related kidney problems. Indeed, most of the individuals were suffering from CAKUT 
involving vesicoureteral reflux and/or bladder bowel dysfunction together with a UTI bacterial 
infection accompanied by acute pyelonephritis (Table 1). 
The sensitivity analysis was conducted to identify model uncertainties and to identify how 
















(intracellular plasma and blood) and fu greatly affected Vd. Interestingly, Hinderling and 
Hartmann[40] studied the pH dependence of drug binding to plasma proteins in human and 
they observed that fu varied along with the pH value depending on the drug. Metabolic 
acidosis is a common complication of chronic kidney disease, which might play a relevant role 
in the PK of the cUTI population. Therefore, it would be very interesting to further study the 
internal pH state in cUTI children and the extent of pH-induced changes in the fu of 
ciprofloxacin under acidemia or alkalemia conditions. 
It should not be ignored that ciprofloxacin appears to be a substrate of OAT3 and P-
glycoprotein (P-gp) transporters. Both transporters are expressed in the proximal tubule of the 
kidney. OAT3 allows its substrates to be up taken from blood, and P-gp to be cleared from the 
proximal tubules to urine [27,28]. Furthermore, P-gp is also expressed in brain and in bile 
canaliculi. Alterations in the expression of those transporters or their functionality due to their 
binding to uremic toxins and inflammatory proteins in different tissues under renal disease 
conditions have been reported [12]. Those alterations may explain a decrease in volume of 
distribution and/or a decreased clearance, opening a research question in the case of 
ciprofloxacin. 
5. Conclusion 
 In conclusion, the presented PBPK model for ciprofloxacin has demonstrated to be 
adequate to simulate different dosing scenarios and to obtain accurate PK predictions in a 
healthy population from 3 months old onwards. Model adaptation of GFR, TS_CLint and CLCYP1A2 
according to KF partially explained the differences seen in the plasma drug concentrations and 
fe vs. time profiles between healthy and cUTI children. Nevertheless, it is necessary to further 
investigate the disease-related changes in cUTI due to the known large heterogeneity in 
patients suffering from CAKUT[11]. This study provides not only an evaluated PBPK model of 
ciprofloxacin for healthy children, but also essential key parameters to suggest hypotheses for 
further fine-tuning of the PBPK model in a cUTI population. 
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Table 1. Clinical characteristics summary of the children from the cUTI clinical trial[11] separated by 
administration type. Table adapted from [11]. 
 IV PO 
Number of participants 10 13 
Proportion females 8 (80%) 6 (46.2%) 
Dose 30-60 minutes infusion of 10-15 
mg/kg every 12 hours   
15-20 mg/kg suspension or tablet 
(maximum 750 mg)  
Diagnosis Acute pyelonephritis: 9 
Cystitis with oral intolerance: 1 
Acute pyelonephritis: 9 
Cystitis: 2 
Recurrent lower UTI: 2 
Comorbidities CAKUT: 1 
CAKUT, heart failure and 
vesicoureteral reflux: 1 
CAKUT and stone disease: 1 
BBD: 2 
Cerebral palsy: 2 
None: 3 
CAKUT: 7 
CAKUT and chronic renal failure: 
1 
CAKUT and BBD: 1 
CAKUT and stone disease: 1 
Neurogenic bladder: 1 
BBD: 1 
Stone disease: 1 
None: 1 
Age in years (median, range) 9.86 (0.51 – 15.5) 6.43 (0.31 – 15.4) 
Serum cystatin C (mg/L) 
(median, range) 
0.71 (0.63 - 0.84) 0.86 (0.61 – 2.88) 
Serum creatinine (mg/dL) 
(median, range) 
0.49 (0.28 - 0.81) 0.64 (0.38 – 1.54) 
CAKUT: Congenital anomalies of the kidneys and urinary tract, BBD: Bladder bowel dysfunction. 22 


















Table 2. Ciprofloxacin physicochemical properties. 
Parameter Value Source 
MW (g/mol) 331 [24] 
MW* (g/mol) 314 [25] 
logP 1.63 [26] 
pKa acidic 6.10 [24] 
pKa basic 8.60 [24] 
Solubility at pH7 (mg/ml) 6.18 [25] 
fu 0.67 [25] 
MW*: Effective Molecular Weight (ciprofloxacin contains a fluorine atom, which leads to a reduction of the 
effective Molecular Weight), logP: logarithm of the octanol-water partition coefficient of the neutral form 
(lipophilicity), pKa acid: negative logarithm of the acid dissociation constant, pKa basic: negative logarithm of the 


















Table 3: Ciprofloxacin specific intestinal permeability and elimination parameters 
Parameter Value Source 




 Estimated from the plasma drug 
concentration 
CLCYP1A2 (ml/min) 20.61  Estimated from the plasma drug 
concentration (IV and PO) [16–21] 
GFR (ml/min/g of organ) 0.266 [5,25] 
TS_CLint (L/min/kg tissue) 1.32 
 
Estimated from the plasma drug 
concentration (IV and PO) [16–21] 
CLBil (ml/min/kg) 1.25 [5] 
CLCYP1A2: cytochrome P450 1A2 mediated clearance, GFR: glomerular filtration rate, 
TS_CLint: tubular secretion clearance, CLBil: biliary clearance.  
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